Skip to main content

Basil Michelle L's Form 4 filing

Haemonetics CorpHAE · filed Sep 19, 2022

Accession no.
0001127602-22-022683
Filed
Sep 19, 2022
Trade date
Sep 15, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.63M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Basil Michelle LCIK 0001699629Officer (EVP and General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 15, 2022Common StockMOption exerciseAcquired+11,154$38.43+$428,648.2251,789Direct
Sep 15, 2022Common StockMOption exerciseAcquired+14,231$41.64+$592,578.8466,020Direct
Sep 15, 2022Common StockMOption exerciseAcquired+3,173$56.57+$179,496.6169,193Direct
Sep 15, 2022Common StockSSaleDisposed−27,769$77.76F3−$2,159,317.4441,424Direct
Sep 15, 2022Common StockSSaleDisposed−6,029$78.50F4−$473,276.535,395Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 15, 2022Common StockMOption exerciseDisposed−11,154$0.00$03,464Direct
Sep 15, 2022Common StockMOption exerciseDisposed−14,231$0.00$04,213Direct
Sep 15, 2022Common StockMOption exerciseDisposed−3,173$0.00$013,564Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)